The drug firm, Roche, which markets Avastin, has not applied for the drug to be used for wet AMD.
Barbara McLaughlan, RNIB campaigns manager for eye health and social care, said patients should continue to be treated with Lucentis until "robust evidence" was available on the safety and effectiveness of Avastin.
12:03 PM
Keshav Bhat


